Drug receives approval as a first-line treatment for metastatic breast cancer in patients whose disease has recurred despite adjuvant therapy.
1998 – Approval received as first-line treatment
Announcement Date: June 1, 1998
Drug receives approval as a first-line treatment for metastatic breast cancer in patients whose disease has recurred despite adjuvant therapy.